Activating Compound | Comment | Organism | Structure |
---|---|---|---|
imatinib | activates cathepsin B and mediates its redistribution to the cytoplasm | Homo sapiens | |
additional information | pharmacological or short hairpin RNA-mediated inhibition of tyrosine kinase BCR-ABL triggers lysosomal membrane permeabilization that culminates in activation and redistribution of cathepsin B into the cytoplasm of chronic myelogenous leukemia cells, in which it triggers directly BCR-ABL degradation | Homo sapiens |
Protein Variants | Comment | Organism |
---|---|---|
additional information | knockdown of cathepsin B in K-562 cells by siRNA | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
CA-074-Me | - |
Homo sapiens | |
additional information | inhibition of cathepsin B increases cell viability in the presence of imatinib | Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
lysosome | - |
Homo sapiens | 5764 | - |
additional information | imatinib mediates redistribution of cathepsin B, Iiatinib or BCR-ABL knockdown induces lysosomal membrane permeabilization that culminates in activation and redistribution of cathepsin B into the cytoplasm of chronic myelogenous leukemia cells | Homo sapiens | - |
- |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
commercial preparation | recombinant enzyme | Homo sapiens | - |
K-562 cell | - |
Homo sapiens | - |
leukemia cell | chronic myelogenous | Homo sapiens | - |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
37 | - |
assay at | Homo sapiens |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
6 | - |
assay at | Homo sapiens |
General Information | Comment | Organism |
---|---|---|
malfunction | cathepsin B confers protection against cell death in clonogenic assays of CD34+ primary cells from chronic myelogenous leukemia patients | Homo sapiens |
additional information | cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers tyrosine kinase BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells, overview | Homo sapiens |